Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Patent: 6,468,263

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,468,263
Title: Implantable responsive system for sensing and treating acute myocardial infarction and for treating stroke
Abstract:Disclosed is a completely implantable system that can detect the occurrence of a myocardial infarction, i.e., a heart attack, and automatically inject a thrombolytic and/or anti-thrombogenic agent into the bloodstream to promptly dissolve the thrombus that caused the myocardial infarction and prevent the formation of additional thrombi. It is well known that a myocardial infarction can be detected from a patient\'s electrocardiogram by noting an ST segment voltage deviation. Upon detection of a myocardial infarction, an ST segment deviation electronic detection circuit within the implanted device can produce an output signal that can cause a thrombolytic and/or anti-thrombogenic agent contained within an implanted, pressurized reservoir to immediately and automatically release medications into the patient\'s bloodstream. A patient warning system is also provided by an audio alarm or an electrical tickle within the human body indicating that a myocardial infarction has been detected. An externally located part of the system, in the form of a patient operated initiator, can be used to trigger the release of medication as soon as a first sign of a stroke has been detected in order to prevent damage to brain tissue that would be caused by that stroke. Thus the system can be used to prevent trissue damage from either a myocardial infarction or a stroke. The implanted system can also send a radio message to an externally located receiver that automatically dials an emergency rescue team to take the patient to a hospital for continuing treatment of a myocardial infarction or a stroke.
Inventor(s): Fischell; Robert E. (Dayton, MD), Fischell; David R. (Fair Haven, NJ), Fischell; Tim A. (Richland, MI)
Assignee: Angel Medical Systems, Inc. (Fair Haven, NJ)
Application Number:09/860,693
Patent Claims:see list of patent claims

Details for Patent 6,468,263

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Microbix Biosystems Inc. KINLYTIC urokinase For Injection 021846 1978-01-16 ⤷  Free Forever Trial 2039-02-26
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 1994-12-22 ⤷  Free Forever Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.